BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,350,000 shares, a decrease of 29.7% from the October 31st total of 1,920,000 shares. Based on an average daily trading volume, of 5,610,000 shares, the short-interest ratio is currently 0.2 days. Currently, 19.6% of the company’s stock are short sold.

BioVie Price Performance

Shares of NASDAQ BIVI traded up $0.09 during mid-day trading on Friday, hitting $2.80. The stock had a trading volume of 1,098,797 shares, compared to its average volume of 2,434,363. The company has a 50 day moving average of $2.27 and a two-hundred day moving average of $1.64. BioVie has a twelve month low of $1.04 and a twelve month high of $33.10.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings results on Monday, September 30th. The company reported ($6.60) earnings per share for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.